Elanco Animal Health Incorporated (ELAN)
- Previous Close
13.57 - Open
13.48 - Bid --
- Ask --
- Day's Range
12.69 - 13.49 - 52 Week Range
7.88 - 16.88 - Volume
5,739,868 - Avg. Volume
4,109,016 - Market Cap (intraday)
6.384B - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-2.50 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.75
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
www.elanco.com9,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ELAN
Performance Overview: ELAN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELAN
Valuation Measures
Market Cap
6.69B
Enterprise Value
12.11B
Trailing P/E
--
Forward P/E
14.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.51
Price/Book (mrq)
1.07
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
-54.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.87%
Return on Assets (ttm)
1.39%
Return on Equity (ttm)
-18.22%
Revenue (ttm)
4.42B
Net Income Avi to Common (ttm)
-1.23B
Diluted EPS (ttm)
-2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
352M
Total Debt/Equity (mrq)
95.07%
Levered Free Cash Flow (ttm)
388M
Research Analysis: ELAN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: ELAN
Daily – Vickers Top Buyers & Sellers for 03/13/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: Elanco Animal Health Inc
Elanco Animal Health, based in Greenfield, Indiana, provides products for both companion and food animals. It became the second-largest animal health company in the world following its acquisition of Bayer's animal health business. Founded in 1954 as part of Eli Lilly, it was spun off from Lilly through an IPO on September 24, 2018. Elanco sells its products in more than 90 countries and has a market capitalization of approximately $7.4 billion. The company has approximately 9,740 full-time employees.
RatingNeutralPrice TargetMarket Digest: CNI, HAL, MMM, ELAN
Market Outlook for 2024
Analyst Report: Elanco Animal Health Inc
Elanco Animal Health, based in Greenfield, Indiana, provides products for both companion and food animals. It became the second-largest animal health company in the world following its acquisition of Bayer's animal health business. Founded in 1954 as part of Eli Lilly, it was spun off from Lilly through an IPO on September 24, 2018. Elanco sells its products in more than 90 countries and has a market capitalization of approximately $5.7 billion. The company has approximately 9,740 full-time employees.
RatingNeutralPrice Target